FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis

N Engl J Med. 2014 Aug 21;371(8):689-91. doi: 10.1056/NEJMp1314385.

Authors

Edward Cox¹, Katherine Laessig

Affiliation

¹ From the Office of Antimicrobial Products, Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

PMID: 25140952
DOI: 10.1056/NEJMp1314385

No abstract available

Publication types

Comment

MeSH terms

Antitubercular Agents / therapeutic use*
Diarylquinolines / therapeutic use*
Female
Humans
Male
Mycobacterium tuberculosis / isolation & purification*
Tuberculosis, Multidrug-Resistant / drug therapy*

Substances

Antitubercular Agents
Diarylquinolines
bedaquiline